Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ESPR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ESPR

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Esperion Therapeutics Inc

ESPR
Current price
1.23 USD +0.05 USD (+4.24%)
Last closed 1.17 USD
ISIN US29664W1053
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 231 892 832 USD
Yield for 12 month -47.88 %
1Y
3Y
5Y
10Y
15Y
ESPR
21.11.2021 - 28.11.2021

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Address: 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.79 USD

P/E Ratio

Dividend Yield

Financials ESPR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ESPR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+332 314 000 USD

Last Year

+116 334 000 USD

Current Quarter

+64 995 000 USD

Last Quarter

+69 113 000 USD

Current Year

+263 713 000 USD

Last Year

+73 067 000 USD

Current Quarter

+33 457 000 USD

Last Quarter

+43 482 000 USD
EBITDA -39 915 000 USD
Operating Margin TTM -34.00 %
Price to Earnings
Return On Assets TTM -7.17 %
PEG Ratio -4.78
Return On Equity TTM -260.79 %
Wall Street Target Price 5.79 USD
Revenue TTM 259 574 000 USD
Book Value -2.17 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -52.80 %
Dividend Yield
Gross Profit TTM 124 118 000 USD
Earnings per share -0.85 USD
Diluted Eps TTM -0.85 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -59.03 %

Stock Valuation ESPR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 1.35
Enterprise Value Revenue 1.58
Price Sales TTM 0.89
Enterprise Value EBITDA 48.73
Price Book MRQ 98.42

Technical Indicators ESPR

For 52 Weeks

0.69 USD 3.94 USD
50 Day MA 0.98 USD
Shares Short Prior Month 26 342 829
200 Day MA 1.72 USD
Short Ratio 4.98
Shares Short 24 113 664
Short Percent 12.22 %